Anthracycline chemotherapy agent (liposomal formulation)

This page covers all Anthracycline chemotherapy agent (liposomal formulation) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA topoisomerase II, Topoisomerase II; DNA, Topoisomerase II, DNA.

Targets

DNA topoisomerase II · Topoisomerase II; DNA · Topoisomerase II, DNA · DNA (intercalating agent); Topoisomerase II

Marketed (2)

• Doxorubicin hydrochloride liposome · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Oncology
  Doxorubicin hydrochloride liposome is a chemotherapy agent encapsulated in liposomes that intercalates into DNA and inhibits topoisomerase II, delivered via liposomal nanoparticles to improve tumor targeting and reduce systemic toxicity.
• ADM · Italian Sarcoma Group · Oncology
  ADM (doxorubicin) is an anthracycline chemotherapy agent that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death.

Phase 3 pipeline (3)

• Daunorubicin/Idarubicin · Institute of Hematology & Blood Diseases Hospital, China · Oncology
  Daunorubicin and idarubicin are anthracycline chemotherapy agents that intercalate into DNA and inhibit topoisomerase II, leading to DNA strand breaks and cancer cell death.
• Liposomal daunorubicin · University of Birmingham · Oncology
  Liposomal daunorubicin is an anthracycline chemotherapy agent encapsulated in liposomes that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cancer cell death.
• treatment Doxorubicin · Assistance Publique Hopitaux De Marseille · Oncology
  Doxorubicin intercalates into DNA and inhibits topoisomerase II, preventing DNA replication and transcription in cancer cells.

Patent intelligence

• anthracycline chemotherapy agent patent landscape — aggregated cliff calendar, attackable patents, originator estates